Nortis
Seattle, US · Delaware corporation · 1 known investors
Biotech
Founders & leadership
SK
Sharon K. EversonDirector
WL
Walter L. RobbDirector
KH
Kriss HammondDirector
TN
Thomas NeumannExecutive Officer, Director
AC
Alan C. NelsonExecutive Officer, Director
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$6MraisedAug 2022 · 3 investors · BiotechnologyRule 506(b)
▶$6MraisedAug 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Makoto ShintaniDirector
- Greg CoronaDirector
- Susan PrestonDirector
- Thomas NeumannExecutive Officer, Director
- Paul ConleyDirector
- Offering amount
- $9.5M
- Amount sold
- $6M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedJan 2022 · 2 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJan 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul ConleyDirector
- Thomas NeumannExecutive Officer, Director
- Susan PrestonDirector
- Greg CoronaDirector
- Offering amount
- $3M
- Amount sold
- $1.5M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedJun 2021 · 3 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJun 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Greg CoronaDirector
- Susan PrestonDirector
- Paul ConleyDirector
- Thomas NeumannExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJun 2021 · 3 investors · BiotechnologyRule 506(b)
▶$1MraisedJun 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul ConleyDirector
- Greg CoronaDirector
- Thomas NeumannExecutive Officer, Director
- Susan PrestonDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$323.2KraisedJul 2017 · 10 investors · BiotechnologyRule 506(b)
▶$323.2KraisedJul 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan C. NelsonExecutive Officer, Director
- Thomas NeumannExecutive Officer, Director
- Mary Ellen HarrisonDirector
- Walter L. RobbDirector
- Sharon K. EversonDirector
- Offering amount
- $500K
- Amount sold
- $323.2K
- First sale
- Aug 2016
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$12.5KraisedJun 2017 · 1 investors · BiotechnologyRule 506(b)
▶$12.5KraisedJun 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas NeumannExecutive Officer, Director
- Sharon K. EversonDirector
- Walter L. RobbDirector
- Mary Ellen HarrisonDirector
- Alan C. NelsonExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $12.5K
- First sale
- Aug 2016
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$408.8KraisedMar 2015 · 1 investors · BiotechnologyRule 506(b)
▶$408.8KraisedMar 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sharon K. EversonDirector
- Walter L. RobbDirector
- Kriss HammondDirector
- Thomas NeumannExecutive Officer, Director
- Alan C. NelsonExecutive Officer, Director
- Offering amount
- $3.4M
- Amount sold
- $408.8K
- First sale
- Mar 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $275.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $252.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $331.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $365K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.